spacer
large
primary
small
spacer
large
primary
small
spacer
large
primary
small
spacer
small
primary
small
left
primary

We’re building a portfolio of medicines targeting
the complexity of cardiometabolic disease

100px
20px
sameTab
select
left

Obesity rarely exists alone. It frequently occurs alongside multiple comorbidities, such as type 2 diabetes, heart disease, obstructive sleep apnea, and joint pain. These conditions can overlap, compound each other, and evolve over time — yet most people are still treated for each one in isolation.

That’s the problem we’re working to solve. Not with one medicine, but with a portfolio built to address obesity and several of its most serious associated conditions.

20px
one
backgroundColor
none
additionalPadding
narrow
additionalMargins
none
left

Built on the biology of incretin hormones

32px
one
spacer
large
primary
small
left
Our cardiometabolic research starts with incretin hormones — gut-derived chemical signals released after eating that regulate blood sugar, appetite, and energy balance. GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonism are the foundations of our approved medicines. But our research extends further: single agonists, a triple agonist, and a selective amylin receptor agonist. The science is still unfolding, and so is our pipeline.
20px
one
backgroundColor
primary-red
additionalPadding
narrow
additionalMargins
none
A scientist in a white lab coat with the “Lilly” logo is using a microscope in a bright laboratory, with glassware and equipment visible in the background.
spacer
large
primary
small
spacer
small
primary
small
left

Why a portfolio — not just a single medicine

32px
one
spacer
large
primary
small
left

Different patients need different tools. A person managing obesity alongside heart disease may have different needs than someone earlier in their treatment journey. Some people may prefer orals, some may prefer injections. What is right for a patient today may change as their disease evolves.

Our strategy reflects that reality across four dimensions:

  • Multiple mechanisms of action — because different biological pathways may be better for different patients or stages of disease.
  • Multiple modalities — injectables and pills, because how a medicine is taken can impact whether it’s taken at all.
  • Multiple conditions — obesity and type 2 diabetes studied in conjunction with some of their most significant comorbidities, rather than in isolation.
  • Every stage of disease — from early intervention to advanced management.
20px
one
backgroundColor
none
additionalPadding
narrow
additionalMargins
none
left

What’s approved today?

32px
one
spacer
large
primary
small
left

We have two molecules in various stages of review and approval by regulators around the globe. These have been recently approved in the US:

  • An injectable dual GIP/GLP-1 receptor agonist for type 2 diabetes, approved by the U.S. FDA in 2022.
  • An injectable dual GIP/GLP-1 receptor agonist for chronic weight management in adults with obesity or overweight, and for moderate-to-severe obstructive sleep apnea in adults with obesity, approved by the U.S. FDA in 2023 and 2024, respectively.
  • A once-daily oral GLP-1 pill for chronic weight management in adults with obesity or overweight, approved by the U.S. FDA in 2026.
20px
one
spacer
large
primary
small
Person sitting indoors on a couch near a window with sheer curtains, with soft natural light illuminating the room and dark wood paneling in the background.
spacer
large
primary
small
spacer
small
primary
small
left

Access matters as much as approval​

32px
one
spacer
large
primary
small
left
Scientific innovation can only fulfill its promise when patients can access the medicines prescribed by their doctors. And Lilly is innovating here too – just like in our clinical research. We're changing how employers think about obesity coverage and helping them find a path to coverage. We’re working with the U.S. government to make obesity medicines available to eligible Medicare beneficiaries at $50/month under the Medicare GLP-1 Bridge. And we launched a direct-to-patient digital pharmacy platform with transparent pricing and home delivery for certain prescribed Lilly medicines.
20px
one
Find independent care options through Lilly Direct
link
https://www.lilly.com/lillydirect/#care
backgroundColor
primary-red
additionalPadding
narrow
additionalMargins
none
left
primary

What the future could hold

100px
sameTab
select
spacer
large
primary
small
Person seated in the driver’s seat of a car at a gas station, looking outward, wearing a knit hat and layered clothing, with fuel pump visible through the window.
spacer
large
primary
small
left

Our approved medicines are the foundation — but the science doesn’t stop there. We’re investing in the next generation of investigational cardiometabolic medicines with the goal of expanding what’s treatable and who can be reached. Our triple agonist has multiple Phase 3 trials reading out in 2026, and Phase 3 trials for our selective amylin receptor agonist are ongoing.

Our goal is the same across all of our efforts: a world where more patients can find a treatment that fits their lives — not the other way around.

20px
one
spacer
large
primary
small
spacer
large
primary
small
backgroundColor
none
additionalPadding
narrow
additionalMargins
none